维持性腹膜透析患者肾性贫血现状分析及治疗进展
Status and Treatment of Renal Anemia in Pa-tients with Maintenance Peritoneal Dialysis
DOI: 10.12677/ACM.2022.12111428, PDF,  被引量    科研立项经费支持
作者: 张宏涛, 张静静：锦州医科大学，临沂市人民医院研究生培养基地，山东 临沂；蔄瑜琳, 王加如, 杨照玉, 籍文捷, 王志奎：山东省临沂市人民医院，山东 临沂；杨 雨, 翟文娟, 李欣绪：山东第一医科大学，山东 济南
关键词: 腹膜透析；贫血；治疗；Peritoneal Dialysis； Anemia； Therapeutics
摘要: 贫血是慢性肾病患者的重要并发症。腹膜透析(peritoneal dialysis, PD)是终末期肾脏病患者最常见的肾脏替代治疗方式之一。在亚太地区尤为普遍，约占总透析人口的2.8%~74.6%。其贫血治疗手段也不断更新，包括新研发的新型低氧诱导因子——脯氨酰羟化酶抑制剂，使用红细胞生成刺激剂、铁剂、输血，我国传统中药制剂也起到了重要作用，未来也可能出现更多纠正贫血的方法供临床医生选择。现就维持性腹膜透析患者肾性贫血治疗方法作一综述，为临床医生提供更多选择。
Abstract: Anemia is an important complication of chronic kidney disease. Peritoneal dialysis (PD) is one of the most common renal replacement treatments in patients with end-stage renal disease. Peritoneal dialysis is particularly common in the Asia-Pacific region, accounting for 2.8% to 74.6% of the total dialysis population. The treatment methods are also constantly updated, including the newly de-veloped new hypoxia-inducible factor—prolyl hydroxylase inhibitors, the use of erythropoiesis stimulants, iron agents, blood transfusion, and Chinese traditional medicine preparations also play an important role. In the future, there may be more methods to correct anemia for clinicians to choose. This article reviews the treatment methods of renal anemia in patients with maintenance peritoneal dialysis to provide more options for clinicians.
文章引用：张宏涛, 蔄瑜琳, 王加如, 杨照玉, 张静静, 籍文捷, 杨雨, 翟文娟, 李欣绪, 王志奎. 维持性腹膜透析患者肾性贫血现状分析及治疗进展[J]. 临床医学进展, 2022, 12(11): 9898-9904. https://doi.org/10.12677/ACM.2022.12111428

参考文献

[1] 中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志, 2021, 101(20): 1463-1502.
[2] Ma, J., Dou, Y., Zhang, H., et al. (2017) Correlation between Inflammatory Biomarkers and Red Blood Cell Life Span in Chronic Hemodialysis Patients. Blood Purification, 43, 200-205. [Google Scholar] [CrossRef] [PubMed]
[3] Li, P.K.T., Choy, A.S.M., Bavanandan, S., et al. (2021) Anemia Manage-ment in Peritoneal Dialysis: Perspectives from the Asia Pacific Region. Kidney Medicine, 3, 405-411. [Google Scholar] [CrossRef] [PubMed]
[4] van Haalen, H., Jackson, J., Spinowitz, B., Milligan, G. and Moon, R. (2020) Impact of Chronic Kidney Disease and Anemia on Health-Related Quality of Life and Work Productiv-ity: Analysis of Multinational Real-World Data. BMC Nephrology, 21, Article No. 88. [Google Scholar] [CrossRef] [PubMed]
[5] Perlman, R.L., Zhao, J., Fuller, D.S., et al. (2019) International Anemia Prevalence and Management in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 39, 539-546. [Google Scholar] [CrossRef] [PubMed]
[6] 齐慧, 周弋, 王丹, 等. 上海市浦东新区成人慢性肾脏病流行现状及与贫血的相关性[J]. 上海预防医学, 2011, 23(11): 529-531, 535.
[7] Zhou, Q.G., Jiang, J.P., Wu, S.J., et al. (2012) Current Pattern of Chinese Dialysis Units: A Cohort Study in a Representative Sample of Units. Chinese Medical Journal, 125, 3434-3439.
[8] Haase, V.H. (2021) Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors in the Treatment of Anemia of Chronic Kidney Disease. Kidney International Supplements (2011), 11, 8-25. [Google Scholar] [CrossRef] [PubMed]
[9] Mima, A. (2021) Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors for Renal Anemia in Chronic Kidney Disease: Advantages and Disadvantages. European Journal of Pharma-cology, 912, Article ID: 174583. [Google Scholar] [CrossRef] [PubMed]
[10] González, F. (1998) Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Undergoing Hemodialysis and Receiving Epoetin. The New England Journal of Medicine, 339, 2023-2024. [Google Scholar] [CrossRef] 
[11] Wish, J.B. (2021) Treatment of Anemia in Kidney Disease: Beyond Erythropoietin. Kidney International Reports, 6, 2540-2553. [Google Scholar] [CrossRef] [PubMed]
[12] Mitsopoulos, E., Lysitska, A., Pateinakis, P., et al. (2020) Efficacy and Safety of a Low Monthly Dose of Intravenous Iron Sucrose in Peritoneal Dialysis Patients. International Urology and Nephrology, 52, 387-392. [Google Scholar] [CrossRef] [PubMed]
[13] Pandey, R., Daloul, R. and Coyne, D.W. (2016) Iron Treatment Strategies in Dialysis-Dependent CKD. Seminars in Nephrology, 36, 105-111. [Google Scholar] [CrossRef] [PubMed]
[14] Gutiérrez, O.M. (2021) Treatment of Iron Deficiency Ane-mia in CKD and End-Stage Kidney Disease. Kidney International Reports, 6, 2261-2269. [Google Scholar] [CrossRef] [PubMed]
[15] Cirillo, L., Somma, C., Allinovi, M., et al. (2021) Ferric Carboxy-maltose vs. Ferrous Sulfate for the Treatment of Anemia in Advanced Chronic Kidney Disease: An Observational Retro-spective Study and Cost Analysis. Scientific Reports, 11, Article No. 7463. [Google Scholar] [CrossRef] [PubMed]
[16] Onken, J.E., Bregman, D.B., Harrington, R.A., et al. (2014) Fer-ric Carboxymaltose in Patients with Iron-Deficiency Anemia and Impaired Renal Function: The REPAIR-IDA Trial. Nephrology Dialysis Transplantation, 29, 833-842. [Google Scholar] [CrossRef] [PubMed]
[17] Hussain, U., Zia, K., Iqbal, R., Saeed, M. and Ashraf, N. (2019) Efficacy of a Novel Food Supplement (Ferfer®) Containing Microencapsulated Iron in Liposomal Form in Female Iron Deficiency Anemia. Cureus, 11, e4603. [Google Scholar] [CrossRef] [PubMed]
[18] Pisani, A., Riccio, E., Sabbatini, M., Andreucci, M., Del Rio, A. and Vis-ciano, B. (2015) Effect of Oral Liposomal Iron versus Intravenous Iron for Treatment of Iron Deficiency Anaemia in CKD Patients: A Randomized Trial. Nephrology Dialysis Transplantation, 30, 645-652. [Google Scholar] [CrossRef] [PubMed]
[19] Floege, J., Funk, F., Ketteler, M., et al. (2020) Iron Kinetics Following Treatment with Sucroferric Oxyhydroxide or Ferric Citrate in Healthy Rats and Models of Anaemia, Iron Overload or In-flammation. Nephrology Dialysis Transplantation, 35, 946-954. [Google Scholar] [CrossRef] [PubMed]
[20] Lewis, J.B., Sika, M., Koury, M.J., et al. (2015) Ferric Citrate Controls Phosphorus and Delivers Iron in Patients on Dialysis. Journal of the American Society of Nephrology, 26, 493-503. [Google Scholar] [CrossRef] 
[21] Umanath, K., Jalal, D.I., Greco, B.A., Umeukeje, E.M., et al. (2015) Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. Journal of the American Society of Nephrology, 26, 2578-2587. [Google Scholar] [CrossRef] 
[22] Block, G., Fishbane, S., Rodriguez, M., et al. (2014) A 12-Week, Double-Blind, Placebo-Controlled Trial of Ferric Citrate for the Treatment of Iron Deficiency Anemia and Reduction of Serum Phosphate in Patients with CKD Stages 3-5. American Journal of Kidney Diseases, 65, 728-736. [Google Scholar] [CrossRef] [PubMed]
[23] Phan, O., Maillard, M., Peregaux, C., et al. (2013) PA21, a New Iron-Based Non Calcium Phosphate Binder, Prevents Vascular Calcification in Chronic Renal Failure Rats. Journal of Pharmacology and Experimental Therapeutics, 346, 281-289. [Google Scholar] [CrossRef] [PubMed]
[24] Iida, A., Kemmochi, Y., Kakimoto, K., et al. (2013) Ferric Citrate Hydrate, a New Phosphate Binder, Prevents the Complica-tions of Secondary Hyper Parathyroidism and Vascular Calcification. American Journal of Nephrology, 37, 346-358. [Google Scholar] [CrossRef] [PubMed]
[25] Gupta, A., Lin, V., Guss, C., Pratt, R., et al. (2015) Ferric Pyrophosphate Citrate Adminis Tered via Dialysate Reduces Erythropoiesis-Stimulating Agent Use and Maintains Hemoglobin in He-modialysis Patients. Kidney International, 88, 1187-1194. [Google Scholar] [CrossRef] [PubMed]
[26] Atkinson, M.A., Kim, J.Y., Roy, C.N., Warady, B.A., White, C.T. and Furth, S.L. (2015) Hepcidin and Risk of Anemia in CKD: A Cross-Sectional and Longitudinal Analysis in the CKiD Cohort. Pediatric Nephrology, 30, 635-643. [Google Scholar] [CrossRef] [PubMed]
[27] Van Eijk, L.T., John, A.S., Schwoebel, F., et al. (2014) Effect of the Antihepcidin Spiegelmer Lexaptepid on Inflammation-Induced Decrease in Serumiron in Humans. Blood, 124, 2643-2646. [Google Scholar] [CrossRef] [PubMed]
[28] Eschbach, J.W., Abdulhadi, M.H., Browne, J.K., et al. (1989) Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal Disease. Results of a Phase III Multicenter Clinical Trial. Annals of Internal Medicine, 111, 992-1000. [Google Scholar] [CrossRef] [PubMed]
[29] Bello, A.K., Ribic, C.M., Cournoyer, S.H., et al. (2018) Transfusion Management of Incident Dialysis Patients in Canada: A Prospective Observational Study. Canadian Journal of Kidney Health and Disease, 5. [Google Scholar] [CrossRef] [PubMed]
[30] St Peter, W.L., Guo, H., Kabadi, S., et al. (2018) Prevalence, Treatment Patterns, and Healthcare Resource Utilization in Medicare and Commercially Insured Non-Dialysis-Dependent Chronic Kidney Disease Patients with and without Anemia in the United States. BMC Nephrology, 19, Article No. 67. [Google Scholar] [CrossRef] [PubMed]
[31] Lopes, M.B., Tu, C., Zee, J., Guedes, M., et al. (2021) A Re-al-World Longitudinal Study of Anemia Management in Non-Dialysis-Dependent Chronic Kidney Disease Patients: A Multinational Analysis of CKD Opps. Scientific Reports, 11, Article No. 1784. [Google Scholar] [CrossRef] [PubMed]
[32] 苏超, 卞显倩, 王刚, 张蕖, 杜婷婷, 何衡杰. 生血宁与多糖铁治疗血液透析患者肾性贫血的疗效比较[J]. 临床肾脏病杂志, 2020, 20(4): 293-296, 321.
[33] Casu, C., Pet-tinato, M., Liu, A., et al. (2020) Correcting β-Thalassemia by Combined Therapies that Restrict Iron and Modulate Erythropoietin Activity. Blood, 136, 1968-1979. [Google Scholar] [CrossRef] [PubMed]
[34] 檀金川, 于晓辉. 滋肾生血方治疗长期血液透析患者肾性贫血的临床观察[J]. 北京中医药, 2013(8): 573-576.
[35] 金伟民, 包晓星. 中西医结合治疗肾性贫血疗效观察[J]. 现代中西医结合杂志, 2004, 13(6): 769-769.
[36] 沈元丽, 王莹. 腹膜透析治疗慢性肾功能衰竭16例分析[J]. 慢性病学杂志, 2010, 12(8): 906-907.

为你推荐